ATRC 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (ATRC)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.3%
업계 평균 (Medical Equipment)	1.7%
애널리스트 예측 (ATRC) (최대 3년)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ATRC 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ATRC 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ATRC 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: ATRC 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

AtriCure 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Further Upside For AtriCure, Inc. (NASDAQ:ATRC) Shares Could Introduce Price Risks After 29% Bounce

AtriCure, Inc. Receives Expanded Ce-Mark Indication for Atriclip®? Devices for the Reduction of Stroke in Patients with Atrial Fibrillation

Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report

AtriCure, Inc. Provides Earnings Guidance for the Full Year 2024

AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care

AtriCure, Inc. Receives Regulatory Approval to Sell AtriClip® Devices in China

AtriCure, Inc. Receives Regulatory Approval to Sell AtriClip® Devices in China

AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward

AtriCure, Inc. to Report Q2, 2024 Results on Jul 30, 2024

AtriCure, Inc.(NasdaqGM:ATRC) dropped from Russell 2000 Value-Defensive Index

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

AtriCure, Inc. Provides Earnings Guidance for the Year 2024

AtriCure, Inc. Announces Launch of the CryoSPHERE®?+ Probe for Post-Operative Pain Management

AtriCure, Inc. to Report Q1, 2024 Results on May 01, 2024

Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

AtriCure, Inc., Annual General Meeting, May 13, 2024

Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Chief Legal Officer notifies of intention to sell stock

Atricure, Inc. Appoints Shlomi Nachman as Director, Member of Each of the Board’s Strategy Committee and Compliance, Quality and Risk Committee

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS exceeds analyst expectations

Atricure, Inc. Provides Earnings Guidance for 2024

AtriCure, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues

Atricure, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Provides Financial Guidance for the Year 2024

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Consensus EPS estimates upgraded to US$0.70 loss

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

AtriCure, Inc. Provides Revenue Guidance for the 2023

AtriCure, Inc. to Report Q3, 2023 Results on Nov 01, 2023

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Now 24% undervalued

Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

Consensus estimates of losses per share improve by 15%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Atricure, Inc. Provides Revenue Guidance for the Year 2023

AtriCure, Inc. to Report Q2, 2023 Results on Jul 25, 2023

AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Independent Director recently sold US$203k worth of stock

Independent Director notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Atricure, Inc. Provides Revenue Guidance for Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Independent Director exercised options to buy US$393k worth of stock.

Now 21% undervalued after recent price drop

Independent Director exercised options to buy US$799k worth of stock.

Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

Consensus EPS estimates fall by 31%

Price target decreased by 7.7% to US$56.33

Full year 2022 earnings: EPS exceeds analyst expectations

What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

AtriCure, Inc. Announces the First Patient Treated in the LeAAPS™ Clinical Trial

AtriCure, Inc. to Report Q4, 2022 Results on Feb 21, 2023

AtriCure, Inc. Provides Earnings Guidance for 2023

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Now 21% undervalued

Price target decreased to US$57.83

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

AtriCure, Inc. Provides Earnings Guidance for the Full Year of 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

AtriCure, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Chief Scientific Officer recently sold US$229k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

Independent Director exercised options to buy US$642k worth of stock.

Insider notifies of intention to sell stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

AtriCure, Inc. Provides Earnings Guidance for the Full Year of 2022